US President Donald Trump has signalled a tariff on imported pharmaceuticals, a policy that is expected to directly hit Australia’s second-largest export to the US.
Jackson Hewett
PYC Therapeutics is facing a $13 million hole as one of its underwriters struggle to fill its share of a shortfall from the biotech’s $146m equity raising.
Cheyanne Enciso
Orthocell has approval to start selling its dental bone repair product into the $US65 million ($109m) Brazilian market.
A group of WA biotechs have urged the State Government to match the existing Federal research and development tax incentive in a move they are certain will attract and retain talent.
WA biotech Orthocell says there’s no need to shift production to the US to dodge Donald Trump’s tariffs as it wins clearance from the Food and Drug Administration to start selling its nerve repair product.
WA biotech Neurotech has secured the backing of the European Commission for its oral cannabinoid drug therapy aimed at treating Rett syndrome, a rare genetic disorder affecting the way the brain develops.
The biotech says its potentially life-saving drug is drawing increasing interest from major pharmaceutical companies in China, where stroke is now the leading cause of death.
WA biotech PYC Therapeutics is tapping shareholders for up to $146 million to fund the development of its four drug candidates.
Low immunisation rates in the US have dented first-half sales for CSL’s flu vaccine business, but the biotech giant says it’s on track to deliver double-digit earnings growth this year.
Alan Tribe-chaired PYC Therapeutics has received regulatory approval to commence human trials for its drug aimed at addressing polycystic kidney disease.
WA telehealth startup BlinkLab has secured its first clinical trial site in the US as it works towards a Food and Drug Administration approval.
WA biotech Orthocell will accelerate plans to enter five new markets this year, buoyed by the early sales traction recorded in Australia, New Zealand and Singapore for its flagship nerve repair product.
Rohan Hockings believes his $600 million WA biotech is edging closer to success after nearly 20 years of life on the Australian Securities Exchange.
Having raised cash from the likes of Chris Ellison, Rod Jones, the McCusker family and Chris Judd, the fast-running biotech stock has been among the ASX’s best performers over the past six weeks.
Sean Smith
Incoming Neurotech boss Anthony Filippis wants to set his feet firmly under the table by fast-tracking the WA biotech’s bid to secure global partnerships for its oral cannabinoid drug therapy.
WA biotech Botanix has shipped the first batch of its sweat-stopper gel to US patients six months after securing Food and Drug Administration approval.
WA biotech Orthocell has started selling its nerve repair product in Singapore, two months after the company received regulatory approval in the country.
A biomedical engineer is set to offer people living with disability a level of independence as easy as looking left and right.
Hannah Cross
Australia’s largest biotech company delivered a 750 per cent return for investors in the decade before the onset of COVID-19. It's shares have since plateaued. What happened?
Amy Bainbridge and Jason Gale
WA biotech Neurotech International has won vital ethics approval for its cannabinoid drug therapy aimed at treating neurological disorders in children.
Strengthening WA’s entrepreneurial ecosystem could see 350 new startups and create as many as 3500 highly skilled jobs, Bankwest Curtin Economics Centre has claimed in a new report.
The nerve-repair company’s shares have been on a tear after a series of positive regulatory and operating updates.
Shares in regenerative medicine company Orthocell soared after the company received regulatory approval for its nerve repair product in Singapore.
A WA listed biotech has failed in its bid to get major backing from the US Food and Drug Administration for its cannabinoid drug therapy aimed at treating neurological disorders in children.
We use cookies so we can improve your experience on this site, analyse traffic and provide you with relevant advertising. To find out more, please see our Cookies Guide.
By continuing to use this site, you agree to our use of cookies.
